Merck to start new study of low-dose HIV drug after FDA's hold

[September 20, 2022]  (Reuters) - Merck & Co Inc said on Tuesday it would start a new late-stage trial of its HIV drug, islatravir, months after the U.S. Food and Drug Administration put a hold on the treatment's trials, citing safety concerns.
 

The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid//File Photo

The FDA has reviewed and agreed with the plan, the company said.

(Reporting by Manas Mishra in Bengaluru; Editing by Anil D'Silva)

[© 2022 Thomson Reuters. All rights reserved.]  This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.